Volume 13, Issue 4 (Autumn 2024)
aumj 2024, 13(4): 290-294 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abbasi Khoshsirat N, Samimisedeh P. A 44-year-old Female Patient with Multiple Sclerosis (MS) being treated with Rituximab who has also tested positive for Covid-19. aumj 2024; 13 (4) :290-294
URL: http://aums.abzums.ac.ir/article-1-1203-en.html
URL: http://aums.abzums.ac.ir/article-1-1203-en.html
1- Cardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran
2- Rajaei Clinical Research Development Unit,Alborz University of Medical Sciences, Karaj, Iran
2- Rajaei Clinical Research Development Unit,Alborz University of Medical Sciences, Karaj, Iran
Abstract: (619 Views)
In March 2020, the World Health Organization announced that the disease caused by the SARS-COV-2 virus (COVID-19) had become a pandemic. This virus was first identified in Wuhan, China. Among the high-risk groups during the COVID-19 pandemic are individuals with multiple sclerosis (MS). Many experienced practitioners in the treatment of MS have noted that it is still unclear whether MS treatment with medication affects the susceptibility to or the clinical severity of COVID-19 infection. However, based on most current articles, medications with the highest levels of immunosuppression (such as CD-20 inhibitors like Rituximab) are likely not suitable for treating MS patients during the COVID-19 epidemic, although there is no scientific evidence to prove this. This study examines a 44-year-old woman with known MS who was treated with Zytux (Rituximab) and received her last dose in early February 2020, coinciding with the onset of the COVID-19 epidemic. On March 21, 2020, less than a month after the injection, she presented with symptoms of cough, fever, and myalgia, and was ultimately diagnosed with COVID-19. The patient was hospitalized and died during admission due to respiratory failure.
Type of Study: Case Report |
Subject:
Special
Received: 2020/10/21 | Accepted: 2022/09/12 | Published: 2024/11/30
Received: 2020/10/21 | Accepted: 2022/09/12 | Published: 2024/11/30
References
1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta bio-medica: Atenei Parmensis. 2020 Mar 19;91(1):157-60.
2. Velavan TP, Meyer CG. The COVID‐19 epidemic. Tropical medicine & international health 2020 Mar;25(3):278. [DOI:10.1111/tmi.13383. PMid:32052514 PMCid:PMC7169770]
3. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients. Journal of medical virology 2020 Jun;92(6):552-5. [DOI:10.1002/jmv.25728. PMid:32104915 PMCid:PMC7228394]
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama 2020 Mar 17;323(11):1061-9. [DOI:10.1001/jama.2020.1585. PMid:32031570 PMCid:PMC7042881]
5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine 2020 Jan 24. [DOI:10.1056/NEJMoa2001017. PMid:31978945 PMCid:PMC7092803]
6. Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology 2020 Feb 2. [DOI:10.1212/WNL.0000000000009507. PMid:32241953]
7. Holmøy T, Torkildsen Ø, Bø L. Treatment of multiple sclerosis under the COVID-19 pandemic. Tidsskrift for Den norske legeforening. 2020.
8. MS international federation. The coronavirus and MS. https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-youneed-to-know/ Lest 14.4.2020.
9. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders. 2020 Apr;39:102073. [DOI:10.1016/j.msard.2020.102073. PMid:32334820 PMCid:PMC7138156]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
